Clinical trial
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 (SRP-1001) in Adult Patients and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
NCT06131983 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 (SRP-1001) in Adult Patients and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Enrolling by invitation
- Start date
- June 19, 2024
- Completion date
- December 31, 2028
- Enrollment
- 60 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.